Singapore: Sweden-based Gyros is expanding its reach in Asia through a tie-up with Bio Laboratories. Its nanoliter-scale immunoassay platform is now available to biopharmaceutical companies in the Singapore region.

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor.

"We are very pleased to expand our reach in Asia through this new partnership with Bio Laboratories, which provides a valuable addition to our recently announced collaboration with GE Healthcare for distribution in Japan, China, Taiwan and Hong Kong," said Mr Erik Walldén, CEO, Gyros. "As our immunoassay platform increases in acceptance within the biopharmaceutical industry, it is ever more vital that we have an experienced and respected network of distributors to ensure the highest possible standards of service and support for our customers."

Benny Wee, Managing Director, Bio Laboratories, said, "Gyros' immunoassay platform is an excellent addition to our extensive range of distribution agreements with high quality, innovative analytical instrument providers. We are delighted to be able to now offer Gyros' products to the biopharmaceutical industry in Singapore."